Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan (Q38048843)

27 August 2017

title

Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan (English)

1 reference

27 August 2017

1

1 reference

27 August 2017

publication date

1 August 2012

1 reference

Expert Review of Cardiovascular Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

10

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

1061-1072

1 reference

The role of the renin-angiotensin system in the development of cardiovascular disease

27 August 2017

cites work

1 reference

Development of heart failure in recent hypertension trials.

21 January 2018

1 reference

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study

21 January 2018

1 reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

21 January 2018

1 reference

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

Antihypertensive therapy and cerebrovascular protection

21 January 2018

1 reference

Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system

21 January 2018

1 reference

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

Clinical practice. Systolic heart failure.

21 January 2018

1 reference

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial

21 January 2018

1 reference

Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial

21 January 2018

1 reference

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

21 January 2018

1 reference

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

21 January 2018

1 reference

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy

21 January 2018

1 reference

Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study

21 January 2018

1 reference

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

21 January 2018

1 reference

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial

21 January 2018

1 reference

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARG

21 January 2018

1 reference

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Asse

21 January 2018

1 reference

In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

21 January 2018

1 reference

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE i

21 January 2018

1 reference

Next generation multifunctional angiotensin receptor blockers

21 January 2018

1 reference

Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study

21 January 2018

1 reference

Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study

21 January 2018

1 reference

The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

21 January 2018

1 reference

21 January 2018

1 reference

Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study

21 January 2018

1 reference

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.

21 January 2018

1 reference

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).

21 January 2018

1 reference

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial

21 January 2018

1 reference

Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?

21 January 2018

1 reference

Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance

21 January 2018

1 reference

A New Option for Therapeutic Management of Patients with Cardiovascular Disease : A Closer Look at the ONTARGET Study

21 January 2018

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluati

21 January 2018

1 reference

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

21 January 2018

1 reference

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial

21 January 2018

1 reference

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

21 January 2018

1 reference

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

21 January 2018

1 reference

Irbesartan in Patients with Atrial Fibrillation

21 January 2018

1 reference

Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoringA metaanalysis of comparative studies

21 January 2018

1 reference

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

21 January 2018

1 reference

Pharmacology of valsartan, an angiotensin II receptor antagonist

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.12.80

1 reference

27 August 2017

1 reference